Evidence map›Paper›PMID 40697217›Full record

ReviewWorld journal of gastrointestinal oncology2025

Advances and challenges in drug repurposing in precision therapeutics of colorectal cancer.

Xin-Ning Yu, Hua-Tao Wu, Bing-Xuan Wu, Shu-Feng Zhi, Yang-Zheng Lan, Wen-Jia Chen, Jing Liu

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in World journal of gastrointestinal oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Xin-Ning YuThe Breast Center, Cancer Hospital of Shantou University Medical College, Shantou 515041, Guangdong Province, China.
Hua-Tao WuDepartment of General Surgery, First Affiliated Hospital of Shantou University Medical College, Shantou 515041, Guangdong Province, China.
Bing-Xuan WuDepartment of General Surgery, First Affiliated Hospital of Shantou University Medical College, Shantou 515041, Guangdong Province, China.
Shu-Feng ZhiDepartment of General Surgery, First Affiliated Hospital of Shantou University Medical College, Shantou 515041, Guangdong Province, China.
Yang-Zheng LanThe Breast Center, Cancer Hospital of Shantou University Medical College, Shantou 515041, Guangdong Province, China.
Wen-Jia ChenThe Breast Center, Cancer Hospital of Shantou University Medical College, Shantou 515041, Guangdong Province, China.
Jing LiuThe Breast Center, Cancer Hospital of Shantou University Medical College, Shantou 515041, Guangdong Province, China. jliu12@stu.edu.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Colorectal cancer (CRC) ranks as the third most common cancer globally and the second leading cause of cancer-related deaths, representing a significant health burden. Despite advancements in traditional treatments such as surgery, chemotherapy, targeted therapy, and immunotherapy, these approaches still face challenges, including high costs, limited efficacy, and drug resistance. Drug repurposing has emerged as a promising strategy for CRC treatment, offering advantages with reduced development timelines, lower costs, and improved drug accessibility. This review explores drug repurposing strategies for CRC, supported by multidisciplinary technologies, and discusses the current challenges in the field.

Indexed as

Colorectal cancerDrug repurposingMultidisciplinary collaborationPrecision therapeuticsTreatment

Identifiers

PMID40697217
PMCPMC12278253

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.